|
CEP120 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.99200722162641E-16 |
| Normal-vs-Stage2 |
1.45330003586963E-09 |
| Normal-vs-Stage3 |
6.11732886568461E-14 |
| Normal-vs-Stage4 |
1.67099667436332E-12 |
| Stage1-vs-Stage2 |
4.264400E-01 |
| Stage1-vs-Stage3 |
2.437000E-01 |
| Stage1-vs-Stage4 |
2.438500E-02 |
| Stage2-vs-Stage3 |
9.614600E-01 |
| Stage2-vs-Stage4 |
3.996600E-01 |
| Stage3-vs-Stage4 |
3.358400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.80638999999205E-05 |
| Normal-vs-Asian |
2.82340040236306E-10 |
| Caucasian-vs-AfricanAmerican |
4.108400E-01 |
| Caucasian-vs-Asian |
8.680000E-01 |
| AfricanAmerican-vs-Asian |
4.058600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.899400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.73627778821128E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
2.03437267032314E-12 |
| Normal-vs-Age(81-100Yrs) |
1.139710E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.721160E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.748400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.161000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.636800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.441800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.659800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.133700E-02 |
| Classical-VS-Follicular |
4.978700E-03 |
| Classical-VS-Other |
1.433630E-01 |
| Classical-VS-Normal |
1.63613567139009E-12 |
| Tall-VS-Follicular |
8.854000E-01 |
| Tall-VS-Other |
6.408000E-01 |
| Tall-VS-Normal |
1.62170277206997E-11 |
| Follicular-VS-Other |
6.682800E-01 |
| Follicular-VS-Normal |
1.88937754330709E-12 |
| Other-VS-Normal |
1.242320E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.18558504627708E-12 |
| N0-vs-N1 |
6.169200E-01 |
|
|
